Analysis

$26B Deal Keeps Opioid Files Of J&J, Distributors Out Of View

By Jeff Overley (January 21, 2022, 7:38 PM EST) -- Document disclosure obligations that attorneys have touted as crucial elements of opioid litigation settlements are absent from a $26 billion resolution that Johnson & Johnson and large drug distributors are close to finalizing, hindering the deal's goal of preventing narcotic abuse, experts say.

The proposed agreement is aimed at ending thousands of lawsuits filed by states and local governments and is geared overwhelmingly toward treatment and prevention of opioid abuse. It calls for J&J to fork over $5 billion and continue sharing clinical trial data with Yale University and for the distributors — AmerisourceBergen Corp., Cardinal Health Inc. and McKesson Corp....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!